Adoption of Leqembi is even slower than expected. EXTON, PA., February 22, 2024 — The 2023 announcement of newly approved
Earlier screening will be needed in the age of biomarkers. EXTON, PA., February 16, 2024 — Millions of people worldwide
Navigating the landscape of Wet AMD Therapies During AMD Awareness Month EXTON, PA., February 8, 2024 — As Age-Related Macular
The addition of UCB’s Bimzelx in the EU and pending US approval adds to the growing momentum of the class,
[Exton, PA., January 18, 2024]—Colleagues from Spherix Global Insights partnered with Cheeriodicals to assemble and deliver care packages to dialysis
With three relatively new drugs, plus a busy pipeline in both systemic lupus erythematosus (SLE) and lupus nephritis (LN), the
But US neurologists also express frustration with current lack of therapies Neurologists in the U.S. are optimistic about the potential
To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than
A chart review completed by Spherix Global Insights shows that more nephrologists are using SGLT2 inhibitors to treat patients with
Despite the expanded armamentarium, Cosentyx has not impacted dermatologists’ perceived unmet need for new HS treatment options, according to Spherix
News pertaining to biosimilars came at a fast and furious pace in 2023. This was the year of the big
According to results of a recent survey, more than 80% of U.S.-based neurologists agreed that a major unmet need in
